|
|
Article: OncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cells CTCs Diagnostic Technology in Women with High-Risk Locally Advanced Breast Cancer.(Clinical report)
- Article from:
- Cancer Weekly
- Article date:
- August 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OncoVista Innovative Therapies, Inc. ("OncoVista") (OTC BB: OVIT.OB) and AdnaGen Ag announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen's molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy (see also OncoVista Innovative Therapies, Inc.).
"M. D. Anderson is dedicated to helping develop novel approaches that may improve the prognosis of patients with malignant diseases," said Dr. Massimo Cristofanilli, Associate Professor of Medicine and the Director of the ...